Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F THOMPSON

Showing results (281-290 of 287) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 287 results.
The British Journal of Dermatology|September 15, 2019
A risk prediction model for the development of subsequent primary melanoma in a population-based cohortA E Cust, C Badcock, J Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
The British Journal of Dermatology|January 17, 2021
A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differencesC Dessinioti, A C Geller, A Stergiopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemC M Balch, S J Soong, J E Gershenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, S J Soong, et al.
Cancer|March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, M B Atkins, et al.
Clinical Genetics|September 17, 2014
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinomaK A W Wadt, L G Aoude, P Johansson, et al.
Pageof 29

Showing results (281-290 of 287) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 287 results.
The British Journal of Dermatology|September 15, 2019
A risk prediction model for the development of subsequent primary melanoma in a population-based cohortA E Cust, C Badcock, J Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2024
Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanomaA M Menzies, S N Lo, R P M Saw, et al.
The British Journal of Dermatology|January 17, 2021
A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differencesC Dessinioti, A C Geller, A Stergiopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging systemC M Balch, S J Soong, J E Gershenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, S J Soong, et al.
Cancer|March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanomaC M Balch, A C Buzaid, M B Atkins, et al.
Clinical Genetics|September 17, 2014
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinomaK A W Wadt, L G Aoude, P Johansson, et al.
Pageof 29